Novo Nordisk STEPs Into Heart Failure
More Success For Obesity And Diabetes Blockbuster Semaglutide
The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.
